Study underscores new paradigm in cancer therapy

[News]

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.

More... (http://www.news-medical.net/news/20130516/Study-underscores-new-paradigm-in-cancer-therapy.aspx)